Article details
Qomel Co. (QOMEL) has signed a SAR 21.56 million service contract with National Unified Procurement Co. (nupco) to supply pharmaceuticals on demand. The agreement, effective for 1,055 days, is expected to positively impact Qomel’s financial statements starting in the second half of 2026. The deal is classified as a service contract and involves no related parties. This partnership underscores Qomel’s strategic expansion in Saudi Arabia’s pharmaceutical sector, aligning with the country’s Vision 2030 goals to strengthen local healthcare infrastructure.
For markets, the agreement signals Qomel’s growing market share in pharmaceutical distribution, which could enhance investor confidence in the company’s long-term revenue potential. The healthcare sector in Saudi Arabia is a key focus area for economic diversification, and such contracts may drive sectoral growth. Traders should monitor Qomel’s quarterly reports for updates on revenue recognition from this deal.
The contract highlights the importance of public-private partnerships in Saudi Arabia’s healthcare ecosystem. For Gulf investors, this deal could indicate broader opportunities in pharmaceutical and medical supply chains. Key watchpoints include Qomel’s operational efficiency in fulfilling the contract and any follow-on agreements with nupco or other government entities.
